文献速递慢性肾脏病肾血管病与高血压

立即与延迟抗逆转录病毒治疗对HIV感染者肾脏健康的长期影响

Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.
PubMed 文献 · Kidney Int · 2024-05-01

START试验随机将4684例未治疗HIV成人分为立即与延迟ART组,中位随访9.3年,肾衰竭或肾脏相关死亡仅8例,两组无显著差异。中位5年综合随访显示eGFR年下降率1.19 mL/min/1.73m2/年,两组差异无统计学意义(差值0.055;95%CI -0.106, 0.217)。研究支持早期ART对肾脏健康的长期安全性。

要点

  • 早期ART不增加长期肾衰竭或肾脏相关死亡风险。
  • 立即与延迟ART组eGFR年下降率无显著差异。
  • 两组确认的UACR≥30 mg/g发生率亦无显著差异。

核心结论

  • 早期ART对HIV感染者肾脏健康具有长期安全性。

研究设计与样本

  • START试验随机对照研究,纳入4684例未治疗且CD4<500 cells/mm3的HIV成人,比较立即与延迟ART。

主要发现

  • 中位9.3年随访,肾衰竭或肾脏相关死亡共8例(立即组3例,延迟组5例)。
  • 中位5年综合随访,eGFR年下降率1.19 mL/min/1.73m2/年,组间差异0.055(95%CI -0.106, 0.217)。
  • 确认的UACR≥30 mg/g发生率组间无显著差异(OR 1.13;95%CI 0.85, 1.51)。

关键数值与推荐

  • eGFR年下降率组间差异0.055 mL/min/1.73m2(95%CI -0.106, 0.217)。
  • UACR≥30 mg/g的OR 1.13(95%CI 0.85, 1.51)。

临床怎么用

  • 临床可放心尽早启动ART,无需因长期肾脏安全性顾虑而延迟治疗。

局限性

  • 肾衰竭或肾脏相关死亡事件数少,可能影响精确估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People with human immunodeficiency virus (HIV) are at risk for chronic kidney disease (CKD) due to HIV and antiretroviral therapy (ART) nephrotoxicity. Immediate ART initiation reduces mortality and is now the standard of care, but the long-term impact of prolonged ART exposure on CKD is unknown. To evaluate this, the Strategic Timing of Antiretroviral Treatment (START) trial randomized 4,684 ART-naïve adults with CD4 cell count under 500 cells/mm3 to immediate versus deferred ART. We previously reported a small but statistically significantly greater decline in estimated glomerular filtration rate (eGFR) over a median of 2.1 years in participants randomized to deferred versus immediate ART. Here, we compare the incidence of CKD events and changes in eGFR and urine albumin/creatinine ratio (UACR) in participants randomized to immediate versus deferred ART during extended follow-up. Over a median of 9.3 years, eight participants experienced kidney failure or kidney-related death, three in the immediate and five in the deferred ART arms, respectively. Over a median of five years of more comprehensive follow-up, the annual rate of eGFR decline was 1.19 mL/min/1.73m2/year, with no significant difference between treatment arms (difference deferred - immediate arm 0.055; 95% confidence interval -0.106, 0.217 mL/min/1.73m2). Results were similar in models adjusted for baseline covariates associated with CKD, including UACR and APOL1 genotype. Similarly, there was no significant difference between treatment arms in incidence of confirmed UACR 30 mg/g or more (odds ratio 1.13; 95% confidence interval 0.85, 1.51). Thus, our findings provide the most definitive evidence to date in support of the long-term safety of early ART with respect to kidney health.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Pelchen-Matthews A, Mocroft A, Ryom L, et al. Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV. Kidney Int. 2024. PMID: 38697479. doi:10.1016/j.kint.2024.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。